The FDA has approved Lumakras, the first treatment for non-small cell lung cancer (NSCLC) with a particular genetic mutation called KRAS G12C.
KRAS mutations and drugs to treat them are among the most talked-about subjects in cancer research these days. Amgen is first to get a new therapy approved by the FDA. Other companies, most notably Mirati Therapeutics, are next in line.
Click here to read the entire article.